TheraGenetics fills new exec VP role
This article was originally published in Clinica
TheraGenetics (London, UK), a personalised medicine diagnostics company, has appointed Robert McBurney as executive vice-president, a newly-created role. Mr McBurney will be responsible for leading the company’s global business development and partnership strategy. He joins from BG Medicine (Massachusetts), where he served as senior vice-president, R&D and chief scientific officer. During his more than 20 years’ experience in the biopharmaceutical industry, Mr McBurney founded start-up biotech firm Differential Proteomics and has served in senior positions at Cambridge NeuroScience and at the Medical Research Council’s neuroendocrinology unit, Newcastle University, National Institutes of Health, and Cambridge University. TheraGenetics is currently commercialising a portfolio of tests to guide and improve treatment of central nervous system disorders.
You may also be interested in...
Three upcoming medical device regulations were discussed at BSI’s Hong Kong Forum in April that will be important to the success of Hong Kong’s voluntary regulatory system, the Medical Device Administrative Control System.
Saudi Arabia has adopted an interim marketing authorisation regulation under which, possibly as early as 2010, only medical devices that have been approved by the Saudi Arabia Food and Drug Administration will be allowed on the market1. Additionally, only medical devices that comply with the regulations in force in the European Union, the US, Canada, Japan or Australia – ie in the jurisdiction of a Global Harmonization Task Force founding member - will be eligible for marketing in the country2,3.
The government of Canada has launched a marketing campaign to encourage consumers and healthcare professionals to use the country’s MedEffect initiative for reporting suspected adverse events related to healthcare products1.